Clinical Trial Detail

NCT ID NCT03419559
Title Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combo With Durvalumab in Non-Small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Iovance Biotherapeutics, Inc.
Indications

lung non-small cell carcinoma

Therapies

LN-145

Durvalumab + LN-145

Age Groups: senior adult

No variant requirements are available.